

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Proposed Single Technology Appraisal

Intravenous zanamivir for treating influenza in hospital ID1196

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u> GlaxoSmithKline (intravenous zanamivir)</p> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • African Health Policy Network • Action Against Allergy • Allergy UK • Asthma UK • Black and Ethnic Minority Diabetes Association • Brain and Spine Foundation • British Liver Trust • British Lung Foundation • Cardiovascular Care Partnership • Diabetes Research and Wellness Foundation • Diabetes UK • Heart UK • Juvenile Diabetes Research Foundation • Kidney Care UK • Liver4Life • Muslim Council of Britain • NAM Publications • National AIDs Trust • National Kidney Federation • Network of Sikh Organisations • Neurological Alliance • South Asian Health Foundation • Specialised Healthcare Alliance • Terrence Higgins Trust <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Respiratory Nurse Specialists • British Geriatrics Society • British Thoracic Society 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Health and safety executive • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Health Protection Network • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • GlaxoSmithKline (zanamivir inhalation powder) • Roche Products (oseltamivir) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Acute Respiratory Infections Group • Breathing Matters • British Association for Lung Research • MRC Clinical Trials Unit • National Institute for Health Research <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health England

Provisional matrix for the proposed technology appraisal of Intravenous zanamivir for treating influenza in hospital ID1196 Issue date: 2018

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Faculty of Public Health • National Pharmacy Association • Primary Care Respiratory Society UK • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Institute of Public Health and Hygiene • Royal Society for Public Health • Royal Pharmaceutical Society • Royal Society of Medicine • UK Clinical Pharmacy Association • UK Clinical Virology Network • UK Health Forum <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS England • NHS Kernow CCG • NHS West Kent CCG • Welsh Government 	<ul style="list-style-type: none"> • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.